Our previous study series reported similar performances of LDHC/LDH-C4, a cancer-testis antigen, in diagnosis and relapse prediction and efficacy evaluation for breast cancer and hepatocellular carcinoma patients (Cui et al., 2020; Cui et al., 2020). This evidence concerns the gene C4A and hepatocellular carcinoma.